Antibiotics

An unusual tetronic acid structurally related to kijanimicin, chlorothricin, tetrocarcin and versipelostatin; has pronounced activity against gram positive bacteria and chlamydia trachomatis; inhibits transcription from the promoter of GRP78; appears to target the phosphatidylinositide-3-kinase/akt signalling pathway.

An unusual tetronic acid structurally related to kijanimicin, chlorothricin, tetrocarcin and versipelostatin; has pronounced activity against gram positive bacteria and chlamydia trachomatis; inhibits transcription from the promoter of GRP78; appears to target the phosphatidylinositide-3-kinase/akt signalling pathway.

It is produced by the strain of Streptomyces rishiriensis MJ 773-88K4. It had strong activity against gram-positive bacteria including staphylococcus, streptococcus, enterococcus, MRSA (MIC is 0.39-0.78 μg/mL) and VRE (MIC is 0.39-0.78 μg/mL). It also has inhibitory effect on L-1210, P388, S180, FS-3, Ehrlich, B16-BL5 and other tumor cell lines (IC50 is 0.06-3.3 μg/mL).

It is produced by the strain of Str. tanashiensis IM 8442T. It's a quinone antibiotic. It has the activity of anti-gram-positive bacteria and some gram-negative bacteria, but the effect of anti-gram-negative bacteria is weak and has no effect on fungi. Lactoquinomycin A has stronger antibacterial activity than Lactoquinomycin B. It inhibits a variety of cell lines including lymphoma L5178Y progenitor, adriamycin resistant, bleomycin-resistant, human leukemia K562, mouse leukemia L-1210 and mouse leukemia P 388 with ID50 (μg/mL) of 0.02, 0.006, 0.008, 0.033, 0.013 and 0.03, respectively.

It is produced by the strain of Str. sp. S-822. It is an oxygen-containing heterocyclic antibiotic. It has anti-gram-positive bacterial and mycoplasma activity.

It is produced by the strain of Str. lasaliensis. It has anti-gram-positive bacteria, protozoa and mycobacterium activity. It is added to feed to prevent coccidiosis in chickens.

It is produced by the strain of Paecilomyces lilacinus A-267. It's a peptide antibiotic. It has a strong anti-pathogenic and non-pathogenic yeast and fungi activity, but also has a medium anti-bacterial effect. It was previously reported that Leucinostatin A and B mixtures inhibited HeLa cells. 0.05 μg/mL of Leucinostatin A for a week (0.25 mg/kg・d) has inhibitory effect on the airy ascites carcinoma entity type, and for ascites type is invalid.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. lincolnensis var. lincolnensis NRRL 2936. It's a sugar antibiotic. It has anti-gram-positive bacteria and spirochete effect, and has weak antibacterial effect on some gram-negative bacteria. It can protect mice infected with Staphylococcus aureus, Streptococcus hemolyticus and dicoccus pneumoniae by oral or subcutaneous injection. It also has effect on leptospira in vivo.

Lincomycin hydrochloride is produced by the strain of Str. lincolnensis var. lincolnensis NRRL 2936. It's a sugar antibiotic. It has anti-gram-positive bacteria and spirochete effect, and has weak antibacterial effect on some gram-negative bacteria. It can protect mice infected with Staphylococcus aureus, Streptococcus hemolyticus and dicoccus pneumoniae by oral or subcutaneous injection. It also has effect on leptospira in vivo. It can prevent and treat respiratory diseases, such as Haemophilus parasuis, infectious pleuropneumonia, mycoplasmosis, atrophic rhinitis, etc.

It is produced by the strain of Str. aureofaciens Tu117. It has strong activity of anti-gram-positive bacterial and no activity against fungi (including yeast).

It is produced by the strain of Str. lividus 2230-N. It's an aminoglycoside antibiotic. It has a broad-spectrum effect against bacteria and mycobacterium, and has no cross-resistance with Streptomyces and penicillium, and has protective effect on mice infected with S. aureus and Pseudomonas aeruginosa.

It is produced by the strain of Str. lomondensis var. lomondensis NRRL 3252. It is an antibiotic of the phenazine derivatives. It has anti-bacterial and fungal effects, but the anti-bacterial effects are weak.

It is produced by the strain of Str. lydicus. It has anti-gram-positive bacterial effect, as well as methicillin-resistant (MRSA) staphylococcus aureus.

It is produced by the strain of Str. lydicus No. 15748. It is an antibiotic that inhibits Gram-negative bacteria by inhibiting peptidoglycan synthesis in bacterial cell walls and promoting the formation of spheroplasts.

It is produced by the strain of Str. parvullus ETH 25000. It has anti-gram-positive bacterial effect, and has weak antibacterial effect on some mycobacteria and candida.

It is produced by the strain of Str. salvialis. It's a polyether antibiotic. It has strong anti-gram-positive bacteria activity, but no anti-gram-negative bacteria activity. It also acts as a pesticide.